IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Re

Posted Apr 26 by Two Blokes

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical com

Source: Two Blokes Trading

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimo

Posted Apr 26 by Two Blokes

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohor

Source: Two Blokes Trading

Massive News: Palantir Technologies Could Explode Because of This

Posted Apr 26 by Two Blokes

Palantir (PLTR 4.63%) stock has pulled back, but a hidden catalyst could change everything. In this video, you

Source: Two Blokes Trading

China has exempted some U.S. imports that the country would struggle to immediately source from elsewhere from its retaliatory t

Posted Apr 26 by Two Blokes

Beijing has been canvassing companies and waiving duties on American goods in sectors where it lacks alternati

Source: Two Blokes Trading

SWKS Deadline: SWKS Investors with Losses in Excess of $100K Have Opportunity to Lead Skyworks Solutions, Inc. Securities Fraud

Posted Apr 26 by Two Blokes

NEW YORK , April 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purc

Source: Two Blokes Trading

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities C

Posted Apr 26 by Two Blokes

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds p

Source: Two Blokes Trading

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder C

Posted Apr 26 by Two Blokes

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST tria

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo\u2122 robotic-assisted surger

Posted Apr 26 by Two Blokes

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted

Source: Two Blokes Trading